This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pacific Biosciences (PACB) Prices Offering of Common Stock
by Zacks Equity Research
Pacific Biosciences of California, Inc. (PACB) recently announced that it has priced its underwritten public offering of 15.4 million shares of its common stock.
DaVita (DVA) Rolls Out Alliance Site Network for CKD Trial
by Zacks Equity Research
DaVita Inc (DVA), through its subsidiary DaVita Clinical Research (DCR), recently announced the expansion of its research services to include Alliance Site Network.
Varian Showcases Halcyon System at DEGRO Meet, Stock Up
by Zacks Equity Research
Shares of Varian Medical Systems Inc. (VAR) rallied almost 1% after the company showcased a new Halcyon radiotherapy treatment system at the 2017 DEGRO meeting, the German radiation oncology society, in Berlin.
TransEnterix Sells Surgery System to Japanese University
by Zacks Equity Research
TransEnterix, Inc. (TRXC), a global medical technology company, recently announced that it has sold a Senhance Robotic Surgery System to a Japanese customer.
Here's Why Phibro Animal Health Is Worth Buying Right Now
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC), has rallied 24.2% over the past three months, ahead of the S&P 500's mere 2.6% gain.
LabCorp to Grow in Precision Med with Cancer Diagnostics Lab
by Zacks Equity Research
LabCorp's (LH) Covance drug development business has recently opened a companion diagnostics laboratory in Morrisville, North Carolina to expand capabilities in precision medicine field.
Abbott Laboratories Up on EPD & Buyouts, Pediatric Weak
by Zacks Equity Research
On Jun 14, we issued an updated research report on Illinois-based Abbott Laboratories (ABT). It is a leading distributor of health care products and services across the globe.
Baxter-Dorizoe Ink Deal to Expand Generic Injectables Line
by Zacks Equity Research
Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company, recently signed an agreement with India-based Dorizoe Lifesciences for expansion of its generic injectables pipeline.
Henry Schein Grows on Strategic Buyouts, Competition Rife
by Zacks Equity Research
On Jun 15, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Haemonetics Rides on Solid Plasma, Slows Blood Center Growth
by Zacks Equity Research
On Jun 13, we issued an updated research report on Haemonetics Corporation (HAE).
Civitas Solutions (CIVI) Extends ADH Platform to New Jersey
by Zacks Equity Research
Civitas Solutions, Inc. (CIVI) recently announced that it has expanded its platform of Adult Day Health services to the state of New Jersey.
Medtronic Resource Centre Opens for Diabetic People in Canada
by Zacks Equity Research
Medtronic plc (MDT) announced that its subsidiary has opened its first Canadian Medtronic Resource Centre to serve diabetic patients in Surrey BC and nearby.
CONMED (CNMD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Shares of Utica, NY-based leading medical technology player, CONMED Corporation (CNMD) rallied to a new 52-week high of $52.79 on Jun 13, closing a little lower at $52.49.
Hill-Rom Rides High on Solid Prospects, Asia-Pacific a Drag
by Zacks Equity Research
On Jun 11, we issued an updated research report on Batesville, IN-based Hill-Rom Holdings, Inc. (HRC) -- a leading global medical device company.
FDA Passes Zimmer Biomet's (ZBH) Zhejiang Facility Issue
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) revealed that the U.S. Food and Drug Administration (FDA) has closed out its 'Warning Letter' related to the company's Zhejiang, China manufacturing facility.
Becton (BDX) with FlowJo to Provide Cloud Platform Services
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has entered into an agreement with FlowJo, LLC.
Mead Johnson-Reckitt Move to Merge, Deal Closes on Jun 15
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) and Reckitt Benckiser have cleared the final regulatory hurdle of their impending merger.
PetMed Express' New Order Sales Increase, Competition Rife
by Zacks Equity Research
On Jun 12, we issued an updated research report on Pompano Beach, FL-based PetMed Express, Inc. (PETS).
Quest Diagnostics to Buy 2 Labs, Grow in Oncology Space
by Zacks Equity Research
Quest Diagnostics (DGX) recently announced agreements to acquire two laboratory businesses in Lewisville, Texas, namely Med Fusion and Clear Point.
Phibro Animal Health (PAHC) Rides High on Solid Prospects
by Zacks Equity Research
On Jun 12, we issued an updated research report on NJ-based Phibro Animal Health Corporation (PAHC) ??? a leading global diversified animal health and mineral nutrition company.
Luminex's (LMNX) VERIGENE Panels Receive Approval in Japan
by Zacks Equity Research
Luminex Corporation (LMNX) recently announced that Japan's Central Social Insurance Medical Council has approved to provide reimbursement for VERIGENE assays.
Inogen (INGN) Up 8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Walgreens-Rite Aid Deal Fall Flat on FTC Blockade?
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) stock took a marginal hit of 0.6% on Friday's close, following the news breakout that the FTC is blocking the impending Rite Aid merger deal.
Masimo (MASI) Presents Utility Study of Oxygen Reserve Index
by Zacks Equity Research
Masimo Corporation (MASI) recently announced data from its study evaluating the potential clinical utility of Masimo Oxygen Reserve Index.
NuVasive (NUVA) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of NuVasive, Inc. (NUVA) scaled a new 52-week high of $81.06 on Jun 9, eventually closing a bit lower at $79.13.